Physician profile
David W Regule
NPI 1730193533
$10,490.71
in general payments reported to CMS, 2019-2025
32 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $1,659 · 2021: $1,687 · 2022: $1,661 · 2023: $1,246 · 2024: $1,328 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,891 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.79 |
| Education | $119.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,939.65 | 2019-2025 | |
| Amgen INC. | $1,166.15 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,146.60 | 2019-2025 | |
| Ucb, INC. | $905.03 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $857.66 | 2019-2025 | |
| Janssen Biotech, INC. | $657.92 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $617.27 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $563.28 | 2019-2025 | Taltz |
| Djo, LLC | $547.58 | 2019-2025 | Aircast, Donjoy |
| Mallinckrodt Hospital Products INC. | $358.87 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $292.64 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.45 | 2020-2024 | Ofev |
| Genentech USA, INC. | $171.89 | 2019-2023 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $168.42 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $146.46 | 2019-2023 | Krystexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $117.72 | 2022-2025 | Purified Cortrophin Gel |
| Pacira Therapeutics, INC. | $92.56 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $80.27 | 2022-2023 | Opsumit |
| Mallinckrodt Enterprises LLC | $55.63 | 2019 | |
| Celgene Corporation | $54.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $53.66 | 2019 | |
| Alexion Pharmaceuticals, INC. | $47.38 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $37.66 | 2021-2023 | |
| Sobi, INC | $27.27 | 2025 | |
| Kyowa Kirin, INC. | $20.83 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.50 | 2021 | |
| Bioventus LLC | $17.14 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.22 | 2024 | |
| Medexus Pharma, INC. | $15.89 | 2019 | |
| Mylan Institutional INC. | $15.65 | 2023 | |
| Merck Sharp & Dohme LLC | $14.38 | 2019 | |
| Radius Health, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Regule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.